The global medical industry experienced a 3% rise in company filings mentions of COVID-19 in Q1 2023 compared with the previous quarter, with the highest share accounted for by Abbott Laboratories with 38% year-on-year increase, according to GlobalData’s analysis of over 639 medical company filings.

Notably, COVID-19 was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of governance and cloud, according to GlobalData.

Of the 50 leading companies in the medical industry, Abbott Laboratories had the greatest increase in references for COVID-19 in Q1 2023, compared with the previous quarter. GlobalData identified 144 COVID-19-related sentences in the company's filings, an increase of 100% in Q1 2023 compared with Q4 2022. Qiagen's mentions of COVID-19 rose by 100% to 113 and Intuitive Surgical's by 100% to 103 and Quest Diagnostics's by 100% to 99 and PerkinElmer's by 100% to 96.

GlobalData's Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for COVID-19 in Q1 2023 was 96.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.